Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
A possible role of arginine vasopressin (AVP) V 1b receptor subtype in stress‐related disorders has been recently highlighted by the discovery of the agonist [1‐deamino‐4‐cyclohexylalanine] AVP (d[Cha 4]AVP) and the antagonist SSR149415. Both compounds have been proposed to target specifically V 1b receptors, since the reported affinities for the related V 1a, V 2 and oxytocin receptors are in the micromolar or submicromolar range. In the present study, we further investigated the binding affinities of d[Cha 4]AVP and SSR149415 at recombinant human vasopressin V 1b(hV 1b) and oxytocin (hOT) receptors expressed in Chinese hamster ovary (CHO) cells and functional properties of both compounds at hV 1b, hV 1a, hV 2 and hOT receptors. d[Cha 4]AVP bound to hV 1b receptors and hOT receptors with p Ki values of 9.68±0.06 and 7.68±0.09, respectively. SSR149415 showed p Ki values of 9.34±0.06 at hV 1b and 8.82±0.16 at hOT receptors. d[Cha 4]AVP stimulated [Ca 2+]i increase in hV 1b‐CHO cells with a pEC 50 value of 10.05±0.15. It showed pEC 50 values of 6.53±0.17 and 5.92±0.02 at hV 1a and hV 2 receptors, respectively, and behaved as a weak antagonist at hOT receptors (p KB=6.31±0.12). SSR149415 inhibited the agonist‐induced [Ca 2+]i increase with p KB values of 9.19±0.07 in hV 1b‐CHO and 8.72±0.15 in hOT‐CHO cells. A functional p Ki value of 7.23±0.10 was found for SSR1494151 at hV 1a receptors, whereas it did not inhibit 20 n M AVP response at hV 2 receptors up to 3 μM. Data obtained confirmed the high potency and selectivity of d[Cha 4]AVP at hV 1b receptors, but revealed that SSR149415, in addition to the high potency at hV 1b receptors, displays a significant antagonism at hOT receptors. British Journal of Pharmacology(2005)146, 744–751. doi:10.1038/sj.bjp.0706383
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age
Antoni, F. A. (1993) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1993.1004 · Cited by 636
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471 · cited 5×
“…they are also significantly expressed in CNS areas such as hippocampus, frontal, piriform and cingulate cortex, caudate putamen, medial habenula, central amygdala and hypothala- mus (Lolait et al., 1995; Hernando et al., 2001; Griebel et al., 2002; Stemmelin et al., 2005).”
BackgroundInfluentialNeumann, Wigger, Torner, Holsboer, & Landgraf (2000) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.2000.00442.x · Cited by 452
Bale, T. L., Davis, A. M., Auger, A. P., Dorsa, D. M., & McCarthy, M. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-07-02546.2001 · Cited by 446 · cited 1×
“A large body of evidence supports the idea that stimulation of OT receptors inhibits HPA axis activation (Neumann et al., 2000) and that OT mediates anxiolytic-like effects after central infusion in rats (Bale et al., 2001).”
BackgroundVasopressin V1b receptor knockout reduces aggressive behavior in male mice
Wersinger, S. R., Ginns, E. I., O'Carroll, A.-M., Lolait, S. J., & Young III, W. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001195 · Cited by 397
Aguilera, G., & Rabadan-Diehl, C. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00196-8 · Cited by 375 · cited 1×
“In particular, it has been proposed that the HPA axis hyperactivity observed in prolonged stressful states and in patients affected by major depression could be maintained by increased secretion of AVP (Aguilera & Rabadan-Diehl, 2000; Scott & Dinan, 2002).”
BackgroundAnxiety and stress responses in female oxytocin deficient mice
Amico, J. A., Mantella, R. C., Vollmer, R. R., & Li, X. (2004) · Journal of Neuroendocrinology · doi:10.1111/j.0953-8194.2004.01161.x · Cited by 327
Female oxytocin-deficient mice display enhanced anxiety-related behavior
Mantella, R. C., Vollmer, R. R., Li, X., & Amico, J. A. (2003) · Endocrinology · doi:10.1210/en.2002-0197 · Cited by 200
Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver
Hems, D. A., & Whitton, P. D. (1973) · Biochemical Journal · doi:10.1042/bj1360705 · Cited by 150
Stemmelin, J., Lukovic, L., Salome, N., & Griebel, G. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300562 · Cited by 112 · cited 2×
“…(Griebel et al., 2002; 2003) suggests that the behavioural effects are not only British Journal of Pharmacology vol 146 (5) related to the antagonism at V1b receptors located in the pituitary, but also to the blockade of central V1b receptors (Griebel et al., 2002; Stemmelin et al., 2005).”
BackgroundDerick, S., Cheng, L. L., Voirol, M. J., Stoev, S., Giacomini, M., Wo, N. C., Szeto, H. H., Ben Mimoun, M., Andres, M., Gaillard, R. C., et al. (2002) · Endocrinology · doi:10.1210/en.2002-220363 · Cited by 76 · cited 5×
“…limited the investigation of the physiological role of these receptors, until the recent discovery of d[Cha4]AVP as the first selective peptido mimetic agonist (Derick et al., 2002), and SSR149415 as the first selective nonpeptide antagonist (Serradeil-Le Gal et al., 2002) at V1b receptors.”
BackgroundResultInfluentialThe vasopressin V1b receptor as a therapeutic target in stress-related disorders
Griebel, G., Simiand, J., Stemmelin, J., Gal, C., & Steinberg, R. (2003) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007033482850 · Cited by 74 · cited 1×
“The anxiolytic and antidepressant profile shown by SSR149415 in preclinical models after systemic administration (Griebel et al., 2002; 2003) suggests that the behavioural effects are not only British Journal of Pharmacology vol 146 (5) related to the antagonism at V1b receptors located in the…”
Background
Cited by
Neumann, I. D., & Landgraf, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.08.004 · Cited by 954
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02303.x · Cited by 423
Vasopressin V1a and V1b Receptors: From Molecules to Physiological Systems
Koshimizu, T.-A., Nakamura, K., Egashira, N., Hiroyama, M., Nonoguchi, H., & Tanoue, A. (2012) · Physiological Reviews · doi:10.1152/physrev.00035.2011 · Cited by 407
MANNING, M., STOEV, S., CHINI, B., DURROUX, T., MOUILLAC, B., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00437-8 · Cited by 296
Metadata
- Authors
- Griffante, C., Green, A., Curcuruto, O., Haslam, C. P., Dickinson, B. A., & Arban, R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2005-11
- Volume
- 146
- Issue
- 5
- Pages
- 744-751
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2005039156
- Cited by
- 60
- References
- 12
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.